Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aveanna Healthcare Holdings (AVAH) Cash & Equivalents (2021 - 2026)

Aveanna Healthcare Holdings (AVAH) has disclosed Cash & Equivalents for 5 consecutive years, with $145.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash & Equivalents rose 85.91% year-over-year to $145.9 million, compared with a TTM value of $145.9 million through Sep 2025, up 85.91%, and an annual FY2024 reading of $84.3 million, up 91.82% over the prior year.
  • Cash & Equivalents was $145.9 million for Q3 2025 at Aveanna Healthcare Holdings, up from $100.7 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $145.9 million in Q3 2025 and bottomed at $17.4 million in Q2 2022.
  • Average Cash & Equivalents over 5 years is $61.5 million, with a median of $48.3 million recorded in 2023.
  • The sharpest move saw Cash & Equivalents crashed 83.61% in 2022, then skyrocketed 128.66% in 2023.
  • Year by year, Cash & Equivalents stood at $121.7 million in 2021, then plummeted by 84.21% to $19.2 million in 2022, then surged by 128.66% to $43.9 million in 2023, then surged by 91.82% to $84.3 million in 2024, then soared by 73.06% to $145.9 million in 2025.
  • Business Quant data shows Cash & Equivalents for AVAH at $145.9 million in Q3 2025, $100.7 million in Q2 2025, and $71.5 million in Q1 2025.